Dysregulated CD8⁺ T cells expressing GATA3 drive a type 2 response limiting CAR T-cell efficacy

1. Requestor must provide a research plan describing how the requested data will be used and the timeframe for the proposed analysis. The research and analysis plan must be in line with the patient consent forms. 3. Requestor must allow Kite, a Gilead company, 60 days notice prior to a submission of an abstract, poster, presentation, or manuscript. Kite will have 60 days to review the publication. 4. Requestor must be in control of the data at all times and cannot transfer to a third party without explicit permission from Gilead. 5. Requestor will not use the data and remove any copies of the data after the analysis is complete. 6. If a publication arises from requestor's research plan, requestor shall reference this data repository and direct all further requestors to EGA. 7. As part of the approval of the request, requestor must sign a data use agreement with Gilead.